Advertisement
News
Advertisement

Dyax withdraws drug application for European approval

Tue, 11/15/2011 - 4:49am
Mass High Tech: The Journal of New England Technology

Dyax Corp. (Nasdaq: DYAZ) on Monday announced it will withdraw a marketing authorization application to sell its Kalbitor drug in Europe. Data on the drug, a treatment for the rare disease hereditary angioedema, was deemed insufficient to demonstrate a positive benefit-risk balance, Dyax said in a news release.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading